Top Markets
Coin of the day
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
Rank in Stocks #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
Share Price
$0.94
Last synced: 2025-02-28
Market Cap
$2.73M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Fresh Tracks Therapeutics, Inc. (FRTX)

Category

P/E ratio for Fresh Tracks Therapeutics, Inc. (FRTX)
P/E ratio as of August 2026 TTM: -0.97
According to Fresh Tracks Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.97. At the end of 2022 the company had a P/E ratio of -0.20.
P/E ratio history for Fresh Tracks Therapeutics, Inc. from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.97 7.03%
2023 -0.91 347.72%
2022 -0.20 -56.38%
2021 -0.47 -48.91%
2020 -0.91 423.34%
2019 -0.17 -88.98%
2018 -1.59 -15.18%
2017 -1.87 -27.20%
2016 -2.57 -36.93%
2015 -4.07 -27.97%
2014 -5.65 72.33%
2013 -3.28 -69.97%
2012 -10.92 -74.95%
2011 -43.61 991.91%
2010 -3.99 -26.36%
2009 -5.42 256.15%
2008 -1.52 -67.18%
2007 -4.64 -46.86%
2006 -8.73 106.01%
2005 -4.24 -5.69%
2004 -4.49 11.16%
2003 -4.04 62.09%
2002 -2.49 -90.60%
2001 -26.53 -35.78%
2000 -41.32 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -3,097.98%
US
30.62 -3,243.66%
NL
- -
CH
- -
KR
18.38 -1,987.17%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.